Sold as Gris-Peg. Every FDA application for this active ingredient: 1 branded and 4 generic.
As of Nov 16, 2026, FDA lists 5 applications for Griseofulvin, Ultramicrosize (sold as Gris-Peg), first approved Apr 16, 1975, with 0 new uses approved and 0 published complete response letters.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Griseofulvin Ultramicrosize | Part D | $696K | +5% | 1,762 |
| Apr 16, 1975 | Gris-PegNDA 50475 ยท New formulation or manufacturer | Bausch | 46 | Marketed |
| Apr 6, 1982 | Fulvicin P/G, Fulvicin P/G 165ANDA 61996 | Chartwell Rx | 2 | Marketed |
| Oct 22, 2012 | Griseofulvin,UltramicrosizeANDA 202545 | Sigmapharm Labs LLC | 0 | Marketed |
| Jan 9, 2014 | Griseofulvin, UltramicrosizeANDA 204371 | Mountain | 1 | Marketed |
| Dec 26, 2018 | Griseofulvin, UltramicrosizeANDA 202805 | Sandoz | 0 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA